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Abstract 
Purpose Campylobacter species are a well recognized but rare cause of 
bloodstream infection.  
Methods Here we reviewed 41 cases of Campylobacter bloodstream infection 
occurring at a single centre in London over 44 years, comprising 0.2% of all 
recorded episodes during this time period.  
Results Patients had a mean age of 46 years and, contrasting with previous 
reports, nearly 50% of our patients did not have significant comorbidities. 
Ciprofloxacin resistance increased over the study period with 35% of isolates 
overall being resistant compared with only 3% exhibiting macrolide resistance. 
Despite a minority of patients receiving appropriate empirical antibiotic 
therapy, overall mortality was only 7%.  
Conclusion Campylobacter bacteraemia remains a rare but significant cause 
of morbidity with a low associated mortality. Underlying immunosuppressive 
conditions are common but by no means universal. In our setting, macrolides 
would be favoured as empirical agents to treat suspected Campylobacter 
enteritis, including cases with associated bacteraemia.  
Key Words: Campylobacter, bacteraemia, food poisoning, gastroenteritis  
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Introduction 
Campylobacter species are a leading cause of communicable gastrointestinal 
disease, particularly among patients with immunodeficiency such as HIV 
infection[1]. First isolated in stool cultures in 1972, [2] Campylobacter is a 
motile, S-shaped, microaerophilic gram-negative bacillus with several 
important virulence factors including flagella, adhesins and production of 
enterotoxin. In most cases, Campylobacter infection causes a self-limiting 
enteritis, however severe or extraintestinal infection does occur rarely. Poultry 
is the major source of zoonotic infection [3] although the organism may also 
be isolated from contaminated water, [4] cattle,[5] dogs,[6] ducks,[7] goats,[8] 
monkeys, [9] sheep,[10] and shellfish [11]. Infection with Campylobacter jejuni 
is most frequently recognised as the pathogen preceding the development of 
Guillain-Barré syndrome, [12] and is associated with other rare post-infectious 
complications including reactive arthritis and Miller Fisher Syndrome [13,14]. 
 
From 2000 to 2012, there were 698,122 laboratory reports of Campylobacter 
to the Health Protection Agency (now Public Health England) in England and 
Wales alone. London accounted for between 3,621 and 6,503 laboratory 
reported cases per annum 
(http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Campylobacte
r/EpidemiologicalData/campyDataEw/ (accessed July 19 2016)). St Thomas's 
Hospital is a large central London teaching hospital providing care to the 
boroughs of Lambeth, Southwark, and Lewisham. These boroughs represent 
greatest number of people living with HIV in the United Kingdom, with a 
diagnosed HIV prevalence of 14.4 per 1,000 residents in Lambeth and 12.2 
per 1,000 residents in Southwark 
(http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139920150. 
(Accessed July 19 2016)). 
 
Despite Campylobacter species being the most common cause of bacterial 
diarrhoea in humans, (http://www.efsa.europa.eu/en/efsajournal/doc/130r.pdf. 
Accessed July 19 2016) Campylobacter bacteraemia is rare and few studies 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 3 
have been published on the topic. The literature features primarily case 
reports from immunocompetent individuals,[15-17] patients with humoral 
immune deficiency such as hypogammaglobulinaemia or 
agammaglobulinaemia, [18-21] or children [22-24]. We present a systematic 
analysis of all episodes of Campylobacter bacteraemia recorded at St 
Thomas' Hospital between 1972 and 2013. 
 
Materials and methods 
Since 1970, the Department of Infectious Diseases has collected prospective 
records of all bloodstream infection episodes at St Thomas’ hospital in 
London. Since 2004 records from Guy’s Hospital, part of the same National 
Health Service Trust, have been included. We defined a bacteraemic episode 
as a hospital attendance with at least one positive blood culture for 
Campylobacter species and a compatible clinical illness. The records are kept 
in an electronic database. 
 
All bacteraemia episodes are classified as either community or hospital-
acquired. Episodes were judged to be community acquired if the illness 
started while the patient was in the community. Hospital acquired episodes 
had their onset after admission, with positive blood cultures being drawn more 
than 48 hours after admission. Information gathered included organism 
species, antibiotic susceptibility, antibiotic treatment, demographic 
information, major comorbidities, clinical outcomes and focus of infection. 
Antibiotic therapy was deemed appropriate if the organism was susceptible to 
the agent in vitro.  
 
A manual broth-based system was used from 1970 until 1982. Since then 
several automated systems have been used, the current system being 
BacT/ALERT 3D (BioMerieux). Organisms were identified based on a typical 
colonial appearance, Gram stain morphology and a positive oxidase test. 
Identification to the species level, where available, was performed by the 
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national reference laboratory (Public Health England, Colindale, UK). 
Susceptibility to antibiotics was determined using disc diffusion. 
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Results 
Case series 
Between 1970 and 2013 a total of 19,161 bloodstream infections were 
recorded on our database. Of these, 45% were community acquired and 55% 
hospital acquired. Campylobacter species was first identified in blood cultures 
from our institution in 1978 (figure 1). We identified a total of 41 
Campylobacter bacteraemia episodes (table 1) in 41 patients. Twenty-seven 
patients (66%) were men, and 14 patients were women. The mean age of our 
cohort was 46 years (standard deviation ± 20.9) and median age was 42 
years (interquartile range 30 to 63 years).  All cases were community 
acquired. 
 
There were six species of Campylobacter accounting for the majority of cases 
(table 2). C. jejuni accounted for 20 (48.8%) of the total cases. Further 
species included C. fetus (n=2, 4.9%), C. coli (n=3, 7.3%), C. hyointestinalis 
(n=1, 2.4%), C. upsaliensis (n=1, 2.4%), and C. ureolyticus (n=1, 2.4%). 
Thirteen (31.7%) organisms were not speciated.  
 
The focus of infection in the majority of cases (70.7%) was the gastrointestinal 
tract (figure 2). We also identified one case of endocarditis, one case of biliary 
sepsis, and one case of septic thrombophlebitis in an intravenous drug 
abuser. A clear focus of infection could not be identified in nine cases (22%). 
Time to blood culture positivity was recorded for thirty-four cultures, (Table 1) 
and the median value was 2 days (interquartile range 2-4 days). 
 
Clinical and laboratory features 
Clinical and laboratory feature are shown in Table 3. All 41 cases documented 
(100%) had experienced a temperature greater than 38°C, 16 cases (44%) 
reported diarrhoeal disease, 14 cases (39%) reported abdominal pain, and 
two cases underwent emergency appendicectomy (5%). Twelve patients 
(39%) did not have any diarrhoea, vomiting or abdominal pain.  
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From our cohort, three patients required treatment in the intensive care unit 
(8%) and the overall mortality was 4.9% (2 of 41). Four patients (11%) were 
known to be infected with HIV (table 4). Of these, one patient had a CD4 
lymphocyte count of 287 cells/mm3 on admission and three patients had a 
count less than 10 cells/mm3. Other underlying illnesses included malignancy 
in three patients (8%), alcoholic liver disease in three patients (8%) and 
diabetes mellitus in three patients (8%).  
 
Antibiotic susceptibility and empirical therapy 
Data on empirical antibiotic use were available in 29 patients. Eight received 
no antibiotics, five were treated with empirical ciprofloxacin (3/5 had diarrhoea 
and 2/5 had presumed biliary infection), four patients received cefuroxime and 
metronidazole; the remaining 12 patients received co-amoxiclav, 
clarithromycin, gentamicin, amoxicillin and flucloxacillin in different 
combinations. Empirical antibiotic therapy was appropriate in only seven of 
the 29 patients (24%). 
 
Erythromycin susceptibility was demonstrated for 29 of 30 isolates tested 
(97%). By contrast, only 17 of 26 isolates (65%) tested were susceptible to 
ciprofloxacin. Notably ciprofloxacin resistance was not detected before 1999 
(nine isolates). However, since 1999 just over 50% of Campylobacter isolates 
from blood exhibited ciprofloxacin resistance. In 2013 our laboratory isolated 
Campylobacter species from stool specimens collected from 290 patients. Of 
these only 53% were susceptible to ciprofloxacin but 98% were susceptible to 
erythromycin.   
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Discussion 
This study describes the clinical and epidemiological features of 
Campylobacter bacteraemia in an urban setting in the United Kingdom (UK). 
We found that C. jejuni was the commonest species implicated and although 
underlying immunosuppressive diseases were common, approximately half of 
the patients had no underlying conditions. Predisposing host risk factors 
described in the literature include male gender and the host immune status 
prior to bacterial exposure [25,26]. In a single centre study in Madrid, Spain, a 
total of 15 out of 64 cases (23%) of Campylobacter bacteraemia were in 
patients with known HIV infection [15]. Previous work in the UK by the Public 
Health Laboratory Service (PHLS) and the Communicable Disease 
Surveillance Centre (CDSC) studied the laboratory reports of Campylobacter 
in England from 1981 to 1991. A total of 267,565 faecal samples were positive 
for Campylobacter, and 394 were associated with bacteraemia with a total of 
7 deaths [16]. The data highlighted that bacteraemia usually followed an acute 
episode of Campylobacter diarrhoea and the incidence of bacteraemia was 
highest among the elderly over 65 years with 5.6 per 1000 diarrhoeal cases, 
compared with 0.3 per 1000 cases among children aged 1 to 4 years.  
 
The pathogenesis of Campylobacter infection remains poorly understood, in 
part due to the lack of an animal model that mimics human gastrointestinal 
disease and identify correlates of virulence [27]. Several virulence factors 
have been identified. Bacterial risk factors for bacteraemia include the 
expression of cytotoxin, flagella and serum resistance although putative 
virulence genes iam, capA, virB and cdtB are not associated with bacteremia 
[28,29]. Several species of Campylobacter may also circumvent the immune 
system by, for example preventing effective stimulation of toll-like receptors 5 
and 9 [30]. Predisposition of patients with HIV/AIDS for opportunistic infection 
with Campylobacter species suggests a role for cell-mediated immunity. It is 
notable that three of the four patients infected with HIV presented in the first 
half of our study, suggesting that the advent of antiretroviral therapy in 1996 
might reduce the susceptibility to Campylobacter bacteraemia. 
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Mortality may appear high but it is important to note this represents a 
snapshot at a single centre. Data from pre-1990 suggests an overall mortality 
of 1.77% in the UK associated with Campylobacter blood stream infections 
however it is recognized that immunocompromise is a risk factor for death. 
Indeed one case series from Barcelona reported a Campylobacter jejuni 
bactereamia mortality rate of 11.5%, significantly associated with HIV 
infection.  
 
Nationally and internationally the proportion of Campylobacter isolates 
exhibiting ciprofloxacin resistance has been increasing since the late 1990’s, 
in human stool samples (30-90% isolates resistant), isolates from blood 
cultures (62.5%) and broiler chicken carcasses (80%) with rates steadily 
increasing [31-34], which mirrors our experience. Erythromycin resistance 
remains relatively rare; though a prolonged outbreak of multidrug resistant C. 
jejuni occurred in Canada between 2003-2013 amongst men who have sex 
with men [35]. With such high rates of resistance, ciprofloxacin is no longer a 
suitable first line antibiotic for patients with suspected Campylobacter enteritis 
or bacteraemia. Although data are scarce to guide empirical treatment, 
macrolides or carbapenems would be favoured agents.  
 
We were unable to estimate the incidence of the Campylobacter bacteraemia 
as our study was hospital-based in a single centre. However our findings are 
consistent with studies published in the literature, in particular the 
predisposition among men, for those with HIV, a high proportion of 
extraintestinal or unknown foci of infection, and the predominance of C.  jejuni 
bacteraemia [17]. Furthermore, studies from France and Israel highlighted the 
higher proportion of Campylobacter bacteraemia among patients with 
malignancy and liver disease, which is consistent with our findings [36,37]. 
Campylobacter enteritis is often associated with systemic upset and fever, 
and it is possible that transient bacteraemia occurs as part of this illness but in 
immunocompetent individuals is rapidly extinguished by the immune 
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response. Notably a recent Swedish study reported an upswing in the 
incidence of Campylobacter bacteraemia in 2014 [38]. Careful investigation 
revealed it was temporally related to changes in detection methods: 
BacT/Alert Plus bottles containing combination of O2, CO2 and N2 replacing 
O2 containing BACTEC bottles. In addition, apparent differences in incidence 
over time or between countries may reflect different thresholds for blood 
culture collection or different duration of incubation of blood culture bottles, 
rather than true variation in incidence. The advent of molecular diagnostic 
techniques means speciation is becoming easier and faster with newer 
species of Campylobacter being detected in blood cultures [39,40].  It is 
notable that the mortality from this infection in our study (4.9%) was low, 
despite the use of frequently inactive empirical antimicrobials, suggesting that 
the organism has intrinsically low virulence.  
 
Two recently reported outbreaks of campylobacteriosis have been linked to 
commercial catering serving chicken livers leading to a novel theory linking 
modern restaurant cooking styles with outbreaks of Campylobacter [41,42]. 
The increasing popularity of chicken livers, particularly served pink or made 
into pate leading to estimations that 19%–52% of livers served commercially 
in the United Kingdom fail to reach 70°C and that predicted Campylobacter 
survival rates are 48%–98%[43] . 
 
Ongoing surveillance would be prudent to ensure the incidence of 
bacteraemia remains low, in particular considering the widespread nature of 
Campylobacter among human and animal hosts and the existing burden of 
gastrointestinal disease.  
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Figure 1. Number of cases of Campylobacter bacteraemia, 1975 to 2013  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
12
Figure 2. Focus of infection for Campylobacter bacteraemia
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CASE YEAR AGE SEX OUTCOME ORGANISM FOCUS GI 
SYMPTOMS 
UNDERLYING 
CONDITION 
TIME TO 
POSITIVITY(
DAYS) 
1 1978 23 M S Campylobacter spp. DIGESTIVE 
TRACT  NR RENAL FAILURE 4 
2 1988 48 F S C. jejuni DIGESTIVE 
TRACT  NONE LIVER CIRRHOSIS 4 
3 1989 32 M S C. jejuni DIGESTIVE 
TRACT  NR 
DIABETES 
RENAL FAILURE 
TRANSPLANT - 
RENAL 
4 
4 1990 80 M S C. jejuni DIGESTIVE 
TRACT NONE MALIGNANCY 4 
5 1992 76 F S C. fetus ENDOCARDIT
IS NONE OTHER NR 
6 1992 30 M S Campylobacter spp. DIGESTIVE 
TRACT  DIARRHOEA NONE 4 
7 1994 42 M S C. jejuni NO FOCUS NONE HIV/AIDS 3 
8 1994 28 M S C. jejuni DIGESTIVE 
TRACT DIARRHOEA NONE 2 
9 1994 38 M S C. jejuni DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN HIV/AIDS 4 
10 1995 38 M S C. jejuni DIGESTIVE 
TRACT  DIARRHOEA NONE 3 
11 1995 30 F S C. jejuni DIGESTIVE 
TRACT  DIARRHOEA PREGNANCY 6 
12 1995 40 M D Campylobacter spp. NO FOCUS DIARRHOEA HIV/AIDS 4 
13 1995 64 M S C. jejuni DIGESTIVE 
TRACT  NONE NONE 2 
14 1997 45 M S C. jejuni DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN 
DIARRHOEA 
LIVER CIRRHOSIS 1 
15 1997 23 F S C. jejuni DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN 
FEVER 
DIARRHOEA 
OTHER 3 
16 1998 85 M D C. jejuni DIGESTIVE 
TRACT DIARRHOEA NONE 2 
17 1998 52 F S Campylobacter spp. DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN 
DIARRHOEA 
NONE 2 
18 1998 28 M S C. jejuni DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN 
FEVER 
DIARRHOEA 
NONE 2 
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19 1998 21 M S Campylobacter spp. DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN 
FEVER 
DIARRHOEA 
NONE 2 
20 1999 29 F S C. jejuni DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN 
FEVER 
DIARRHOEA 
NONE 5 
21 2002 37 M S Campylobacter spp. DIGESTIVE 
TRACT  NONE OTHER 2 
22 2002 37 M S Campylobacter spp. DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN 
FEVER 
DIARRHOEA 
OTHER 3 
23 2002 55 M S C. jejuni NO FOCUS NONE HIV/AIDS 2 
24 2002 60 M S C. upsaliensis NO FOCUS NONE OTHER 2 
25 2002 62 M S C. hyointestinalis DIGESTIVE 
TRACT  DIARRHOEA 
GALLSTONES 
LIVER CIRRHOSIS 3 
26 2003 1 day F S C. fetus NO FOCUS NONE PREMATURE 4 
27 2004 74 M S Campylobacter spp. DIGESTIVE 
TRACT  
DIARRHOEA 
FEVER DIABETES 2 
28 2007 65 F S C. jejuni NO FOCUS NONE DIABETES 2 
29 2007 20 F S C. jejuni NO FOCUS NONE OTHER NR 
30 2009 80 F S C. coli BILE (ERCP) NR MALIGNANCY NR 
31 2009 46 M S C. coli DIGESTIVE 
TRACT  NR 
INTRAVENOUS 
DRUG USE 
LIVER CIRRHOSIS 
4 
32 2009 63 F S Campylobacter spp. NO FOCUS NR MALIGNANCY NR 
33 2011 38 F S Campylobacter spp. DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN 
FEVER 
DIARRHOEA 
NONE 2 
34 2011 63 M S Campylobacter spp. DIGESTIVE 
TRACT  NR 
MALIGNANCY 
TRANSPLANT - 
BONE MARROW 
NR 
35 2011 21 F S Campylobacter spp. DIGESTIVE 
TRACT 
ABDOMINAL 
PAIN 
FEVER 
NONE 1 
36 2012 83 F S C. coli DIGESTIVE 
TRACT  
ABDOMINAL 
PAIN 
DIARRHOEA 
NONE 2 
37 2013 53 M S Campylobacter spp. DIGESTIVE 
TRACT  DIARRHOEA 
DIABETES 
RENAL FAILURE 2 
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38 2013 77 M D C. jejuni NO FOCUS NONE MALIGNANCY NR 
39 2013 42 M S C. ureolyticus 
SEPTIC  
THROMBOPH
LEBITIS 
FEVER INTRAVENOUS 
DRUG USE NR 
40 2013 35 M S C. jejuni DIGESTIVE 
TRACT 
ABDOMINAL 
PAIN 
FEVER 
DIARRHOEA 
NONE NR 
41 2013 29 M S C. jejuni DIGESTIVE 
TRACT FEVER NONE 2 
 
 
 
Table 1. Case series of Campylobacter bacteraemia, 1970 to 2013 
Time to positivity = time for blood cultures to become positive. S = Survived, D 
= Died NR = not recorded.  
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ORGANISM ISOLATED NUMBER OF PATIENTS (%) 
YEAR FIRST 
ISOLATED 
Campylobacter jejuni 20 (48.8) 1989 
Campylobacter fetus 2 (4.9) 1992 
Campylobacter coli 3 (7.3) 2002 
Campylobacter hyointestinalis 1 (2.4) 2002 
Campylobacter upsaliensis 1 (2.4) 2002 
Campylobacter ureolyticus 1 (2.4) 2013 
Campylobacter (unspeciated) 13 (31.7) 1978 
 
 
 
Table 2. Campylobacter species isolated from blood from 1970 to 2013.   
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SYMPTOM NUMBER OF PATIENTS (%) 
FEVER 35 (85) 
DIARRHOEA 19 (46) 
ABDOMINAL PAIN 13 (32) 
JOINT PAIN 3 (7) 
HEADACHE 4 (10) 
VOMITING 2 (5) 
WEIGHT LOSS 3(7) 
 
 
 
Table 3. Clinical features in patients with Campylobacter bacteraemia 
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UNDERLYING 
CONDITION 
NUMBER (%) 
PREMATURITY 1 (2.4) 
PREGNANCY 1 (2.4) 
INTRAVENOUS DRUG 
USE 
2 (4.9) 
RENAL FAILURE 3 (7.3) 
DIABETES 4 (9.8) 
LIVER FAILURE 4 (9.8) 
HIV/AIDS 4 (9.8) 
MALIGNANCY 5 (12.2) 
NONE 19 (46.3) 
 
 
 
Table 4. Underlying conditions of patients with Campylobacter 
bacteraemia.  
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